Yoo KH, Park SJ, Han HS, et al. - In this multicentre, double‐blind, randomized, parallel, active‐controlled Phase III clinical trial with two stages, researchers sought to examine the non‐inferiority of letibotulinum toxin A (LeBA) vs the existing onabotulinum toxin A (OnBA) for the treatment of crow's feet lines (CFL). In total, 240 individuals were randomized to either the test (LeBA) or control (OnBA) group. At the same doses, this analysis revealed that LeBA was just as effective and safe as OnBA for the treatment of CFL.